Definium Therapeutics (NASDAQ:DFTX) said it expects to report top-line results from its Phase III VOYAGE study of DT120 ODT in generalized anxiety disorder during the week of Aug. 10, following positive Phase III results in major depressive disorder reported in June.
Chief Executive Officer Rob Bar
Definium Therapeutics (NASDAQ:DFTX) Chief Financial Officer Brandi Roberts said the company is preparing for several key clinical and regulatory milestones for DT-120, including anticipated Phase III data in major depressive disorder later this quarter and ongoing Phase III work in generalized anxie
